Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression

PURPOSE: To explore the activity of dasatinib in combination with docetaxel, gemcitabine, topotecan and doxorubicin in ovarian cancer cells. EXPERIMENTAL DESIGN: Cells with previously determined SRC pathway and protein expression (SRC pathway/SRC protein: IGROV1, both high; SKOV3, both low) were tre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Teoh, Deanna, Jia, Jingquan, Nixon, Andrew B., Grace, Lisa, Adams, David J., Murphy, Susan K., Secord, Angeles Alvarez
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3946897/
https://ncbi.nlm.nih.gov/pubmed/24407585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000056
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares